# Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention

> **NCT00404781** · PHASE4 · COMPLETED · sponsor: **Shenyang Northern Hospital** · enrollment: 305 (actual)

## Conditions studied

- Ischemic Heart Disease
- Acute Coronary Syndromes

## Interventions

- **DRUG:** cilostazol in addition to aspirin and clopidogrel

## Key facts

- **NCT ID:** NCT00404781
- **Lead sponsor:** Shenyang Northern Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 305 (ACTUAL)
- **Last updated:** 2009-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00404781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00404781, "Effects of Optimized Antiplatelet Treatment After Percutaneous Coronary Intervention". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00404781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*